NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Ownership - Who owns 4d Molecular Therapeutics?

Insider buying vs selling

Have 4d Molecular Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when FDMT insiders and whales buy or sell their stock.

FDMT Shareholders

What type of owners hold 4d Molecular Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bvf Inc9.91%4,629,289$30.97MInstitution
Ra Capital Management LP9.77%4,563,211$30.53MInstitution
Ra Capital Management LP9.77%4,563,211$30.53MInsider
Viking Global Investors LP9.10%4,247,914$28.42MInsider
Goldman Sachs Group Inc8.91%4,159,264$27.83MInstitution
Blackrock Inc8.59%4,010,755$26.83MInstitution
Vanguard Group Inc5.86%2,736,671$18.31MInstitution
Novo Holdings A4.28%2,000,000$13.38MInstitution
Janus Henderson Group PLC3.76%1,754,410$11.74MInstitution
Federated Hermes Inc3.57%1,667,338$11.15MInstitution

1 of 3

FDMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FDMT76.16%23.84%
ALT37.22%62.78%Net SellingNet Buying
LCTX39.04%60.96%Net Buying
IMAB4.99%0.00%
ALEC59.85%40.15%Net SellingNet Selling

4d Molecular Therapeutics Stock Ownership FAQ

Who owns 4d Molecular Therapeutics?

4d Molecular Therapeutics (NASDAQ: FDMT) is owned by 86.50% institutional shareholders, 27.08% 4d Molecular Therapeutics insiders, and 0.00% retail investors. Ra Capital Management LP is the largest individual 4d Molecular Therapeutics shareholder, owning 4.56M shares representing 9.77% of the company. Ra Capital Management LP's 4d Molecular Therapeutics shares are currently valued at $30.39M.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.